Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

ReDU: a framework to find and reanalyze public mass spectrometry data

Abstract

We present ReDU (https://redu.ucsd.edu/), a system for metadata capture of public mass spectrometry-based metabolomics data, with validated controlled vocabularies. Systematic capture of knowledge enables the reanalysis of public data and/or co-analysis of one’s own data. ReDU enables multiple types of analyses, including finding chemicals and associated metadata, comparing the shared and different chemicals between groups of samples, and metadata-filtered, repository-scale molecular networking.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: ReDU framework and illustrative public ReDU data analyses.
Fig. 2: Repository-scale molecular networking of public data in ReDU.

Similar content being viewed by others

Data availability

Source data for the results presented in this paper are available on GitHub (https://github.com/mwang87/ReDU-MS2-GNPS/tree/master/examples). All curated sample information can be downloaded from the ReDU homepage (https://redu.ucsd.edu/) by selecting ‘Download Database’. The current version of the ReDU information used to generate the results in this paper is archived in the GNPS/MassIVE repository (http://gnps.ucsd.edu). The accession number is MSV000084206 (https://doi.org/10.25345/C5407D).

Code availability

All software is citable using https://doi.org/10.5281/zenodo.3924422. Up-to-date developments of ReDU are available in GitHub (https://github.com/mwang87/ReDU-MS2-GNPS), with corresponding documentation (https://github.com/mwang87/ReDU-MS2-Documentation).

References

  1. Wang, M. et al. Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking. Nat. Biotechnol. 34, 828–837 (2016).

    Article  CAS  Google Scholar 

  2. Haug, K. et al. MetaboLights: a resource evolving in response to the needs of its scientific community. Nucleic Acids Res. 48, D440–D444 (2020).

    PubMed  CAS  Google Scholar 

  3. Sud, M. et al. Metabolomics Workbench: an international repository for metabolomics data and metadata, metabolite standards, protocols, tutorials and training, and analysis tools. Nucleic Acids Res. 44, D463–D470 (2016).

    Article  CAS  Google Scholar 

  4. Federhen, S. The NCBI Taxonomy database. Nucleic Acids Res. 40, D136–D143 (2012).

    Article  CAS  Google Scholar 

  5. Mungall, C. J., Torniai, C., Gkoutos, G. V., Lewis, S. E. & Haendel, M. A. Uberon, an integrative multi-species anatomy ontology. Genome Biol. 13, R5 (2012).

    Article  Google Scholar 

  6. Schriml, L. M. & Mitraka, E. The Disease Ontology: fostering interoperability between biological and clinical human disease-related data. Mamm. Genome 26, 584–589 (2015).

    Article  Google Scholar 

  7. Scheubert, K. et al. Significance estimation for large scale metabolomics annotations by spectral matching. Nat. Commun. 8, 1494 (2017).

    Article  CAS  Google Scholar 

  8. Sumner, L. W. et al. Proposed minimum reporting standards for chemical analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics 3, 211–221 (2007).

    Article  CAS  Google Scholar 

  9. Vázquez-Baeza, Y., Pirrung, M., Gonzalez, A. & Knight, R. EMPeror: a tool for visualizing high-throughput microbial community data. Gigascience 2, 1–4 (2013).

    Article  Google Scholar 

  10. Hammons, J. L., Jordan, W. E., Stewart, R. L., Taulbee, J. D. & Berg, R. W. Age and diet effects on fecal bile acids in infants. J. Pediatr. Gastroenterol. Nutr. 7, 30–38 (1988).

    Article  CAS  Google Scholar 

  11. Robertson, R. C., Manges, A. R., Finlay, B. B. & Prendergast, A. J. The human microbiome and child growth—first 1000 days and beyond. Trends Microbiol. 27, 131–147 (2019).

    Article  CAS  Google Scholar 

  12. Martin, C. B., Hales, C. M., Gu, Q. & Ogden, C. L. Prescription drug use in the United States, 2015–2016 (NCHS Data Brief no. 334) https://www.cdc.gov/nchs/products/databriefs/db334.htm (2019).

  13. Omura, S. et al. A new alkaloid Am-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J. Antibiot. 30, 275–282 (1977).

    Article  CAS  Google Scholar 

  14. Peypoux, F., Bonmatin, J. M. & Wallach, J. Recent trends in the biochemistry of surfactin. Appl. Microbiol. Biotechnol. 51, 553–563 (1999).

    Article  CAS  Google Scholar 

  15. Ernst, M. et al. Molnetenhancer: enhanced molecular networks by integrating metabolome mining and annotation tools. Metabolites 9, 144 (2019).

    Article  CAS  Google Scholar 

  16. Wynalda, M. A., Hutzler, J. M., Koets, M. D., Podoll, T. & Wienkers, L. C. In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab. Dispos. 31, 878–887 (2003).

    Article  CAS  Google Scholar 

  17. Protsyuk, I. et al. 3D molecular cartography using LC–MS facilitated by Optimus and ’ili software. Nat. Protoc. 13, 134–154 (2018).

    Article  CAS  Google Scholar 

  18. Wilkinson, M. D. et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci. Data 3, 160018 (2016).

    Article  Google Scholar 

  19. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the individuals involved in the funding, administration, sample collection and data acquisition of the public data used in ReDU. We recognize the financial support of the US National Institutes of Health (P41 GM103484, R03 CA211211, R01 LM013115 and R01 GM107550), the Sloan Foundation (R.K.), the Gordon and Betty Moore Foundation (P.C.D., N.B., K.L.M.), a FAPESP fellowship (2018/24865-4), the American Society for Mass Spectrometry (A.K.J.), NSF grants IOS-1656481 (P.C.D. and A.M.C.R.) and ABI-1759980, Netherlands eScience Center no. ASDI.2017.030 (J.J.J.v.d.H.), the Krupp Endowed Fund (R. Coras), the US Office of Naval Research (N00014-15-1-2809) and the University of California, San Diego, Center for Microbiome Innovation SEED grants.

Author information

Authors and Affiliations

Authors

Contributions

A.K.J., M.W. and P.C.D. developed the ReDU concept. A.K.J., M.W. and C.M.A. wrote code and engineered the ReDU infrastructure. A.K.J., C.M.A., R.S.A., S.A., A.A.A., G.A., A.T.A., A. Bauermeister, S.B., A. Bouslimani, A.M.C.R., R. Chaar, R. Coras, E.O.E., J.J.J.v.d.H., J.M.G., E.C.G., M.H., K.L.J., Z.K., A.L.G., A.L., L.-I.M., K.L.M., M.J.M., A.V.M., R.C.M., Y.A.M.G., N.H.N., L.F.N., M.E., M.N.E., M.P., D.P., R.Q., N.S., F.V., A.V. and K.C.W. curated metadata enabling ReDU. A.K.J., M.W., C.M.A., S.A.J., L.-I.M., M.E., J.J.J.v.d.H., J.M.G., M.P. and P.C.D. tested the ReDU infrastructure and provided feedback. A.K.J., M.W., C.M.A., M.E., J.J.J.v.d.H., R.K., N.B. and P.C.D. wrote and edited the manuscript. R.K., N.B. and P.C.D. provided supervision and funding support.

Corresponding author

Correspondence to Pieter C. Dorrestein.

Ethics declarations

Competing interests

P.C.D. is a scientific advisor for Sirenas LLC, Galileio and Cybele Microbiome and scientific advisor and co-founder of Enveda. M.W. is a founder of Ometa Labs LLC. A.A. is a consultant for Ometa Labs LLC.

Additional information

Peer review information Allison Doerr was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 Repository-scale molecular cartography enabled by ReDU.

ReDU samples with latitude and longitude information, n = 34,003, were grouped by latitude and longitude (n = 2068 different locations) and plotted colored by number of annotations per file (log10 scaled).

Extended Data Fig. 2 Comparison of bacterial cultures using Group Comparator in ReDU.

Bacterial cultures of 1280|Staphylococcus aureus (n = 49), 1423|Bacillus subtilis (n = 89), and 1883|Streptomyces (n = 7) were compared and chemical differences are illustrated by pyroGlu-Ile, staurosporine, and surfactin-C14.

Extended Data Fig 3 Repository-scale molecular networking of human blood (n = 711), fecal (n = 5,097), and urine (n = 307) supplemented by MolNetEnhancer.

(a) MolNetEnhancer enhanced molecular network in which components are colored based on Classyfire chemical class prediction. (b) Number of nodes per Classyfire chemical class prediction. Nodes without a match in Classyfire are not displayed.

Extended Data Fig 4 Molecular cartography of the distribution of drugs on the human body visualized using ili.

Descaladinose azithromycin, a drug metabolite of azithromycin, distribution in human (n = 17,117; normalized by the number of files per sample).

Supplementary information

Supplementary Information

Supplementary Discussion, Supplementary Table 1 and Supplementary Figs. 1–5.

Reporting Summary

Supplementary Table 2

Tabulated information for proposed clindamycin metabolites based on repository-scale molecular networking in ReDU.

Supplementary Video 1

The empirically observed UBERON-based location of drugs and drug metabolites observed in metabolomics data 28 August 2019–10 July 2020 processed through ReDU.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jarmusch, A.K., Wang, M., Aceves, C.M. et al. ReDU: a framework to find and reanalyze public mass spectrometry data. Nat Methods 17, 901–904 (2020). https://doi.org/10.1038/s41592-020-0916-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41592-020-0916-7

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research